No Data
No Data
H.C. Wainwright Maintains GlycoMimetics(GLYC.US) With Hold Rating
H.C. Wainwright Remains a Hold on GlycoMimetics (GLYC)
GlycoMimetics To Conduct Additional Clinical Trial For Uproleselan In R/R Acute Myeloid Leukemia After FDA Meeting; Initiates Strategic Review And Corporate Restructuring, Reducing Workforce By 80%; Engages Lucid Capital Markets As Strategic Advisor;...
Express News | GlycoMimetics Inc - FDA Requires Additional Trial for Uproleselan in Aml
Express News | GlycoMimetics Inc - Cash Expected to Fund Company Into Q2 2025
Express News | GlycoMimetics Inc: Will Reduce Its Workforce by Approximately 80%
No Data